Other equities analysts have also recently issued research reports about the company. Mizuho reaffirmed a “buy” rating and set a $72.00 target price on shares of FibroGen in a research note on Monday, November 18th. ValuEngine upgraded FibroGen from a “hold” rating to a “buy” rating in a report on Friday, January 3rd. Finally, Zacks Investment Research lowered FibroGen from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company’s stock. FibroGen presently has a consensus rating of “Hold” and a consensus price target of $55.80.
NASDAQ:FGEN traded up $0.61 on Tuesday, hitting $43.09. 12,596 shares of the company’s stock traded hands, compared to its average volume of 567,195. The company has a current ratio of 9.01, a quick ratio of 8.95 and a debt-to-equity ratio of 0.07. FibroGen has a 1 year low of $32.33 and a 1 year high of $61.23. The firm has a 50-day moving average price of $44.64 and a 200-day moving average price of $42.57. The company has a market cap of $3.73 billion, a PE ratio of -41.96 and a beta of 1.86.
FibroGen (NASDAQ:FGEN) last released its earnings results on Monday, November 11th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.02. FibroGen had a return on equity of 7.33% and a net margin of 11.81%. The company had revenue of $33.17 million for the quarter, compared to analysts’ expectations of $31.61 million. During the same quarter in the previous year, the business posted ($0.50) EPS. The business’s revenue for the quarter was up 14.3% on a year-over-year basis. On average, research analysts forecast that FibroGen will post -0.16 EPS for the current fiscal year.
In other FibroGen news, Director Kalevi Kurkijarvi sold 6,000 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $38.27, for a total value of $229,620.00. Following the sale, the director now directly owns 34,400 shares in the company, valued at $1,316,488. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider K Peony Yu sold 3,420 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $46.68, for a total value of $159,645.60. Following the completion of the sale, the insider now owns 172,617 shares in the company, valued at $8,057,761.56. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 38,295 shares of company stock worth $1,632,226. 8.96% of the stock is currently owned by company insiders.
Institutional investors have recently bought and sold shares of the business. Farallon Capital Management LLC grew its holdings in shares of FibroGen by 85.7% during the second quarter. Farallon Capital Management LLC now owns 1,700,000 shares of the biopharmaceutical company’s stock worth $76,806,000 after buying an additional 784,421 shares in the last quarter. Hillhouse Capital Advisors LTD. boosted its position in FibroGen by 36.0% during the second quarter. Hillhouse Capital Advisors LTD. now owns 2,724,519 shares of the biopharmaceutical company’s stock valued at $123,094,000 after purchasing an additional 721,232 shares during the last quarter. Nuveen Asset Management LLC boosted its position in FibroGen by 3,168.1% during the second quarter. Nuveen Asset Management LLC now owns 418,312 shares of the biopharmaceutical company’s stock valued at $18,899,000 after purchasing an additional 405,512 shares during the last quarter. Invesco Ltd. boosted its position in FibroGen by 211.3% during the second quarter. Invesco Ltd. now owns 451,545 shares of the biopharmaceutical company’s stock valued at $20,401,000 after purchasing an additional 306,510 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. boosted its position in FibroGen by 63.0% during the second quarter. Amundi Pioneer Asset Management Inc. now owns 417,790 shares of the biopharmaceutical company’s stock valued at $18,876,000 after purchasing an additional 161,488 shares during the last quarter. 68.71% of the stock is currently owned by institutional investors.
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
See Also: What does the Dogs of the Dow mean?
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.